A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Multicenter Phase 2 Induction Study With Long-Term Extension to Evaluate the Clinical Activity and Safety of Oral NX-13 in Participants w/ Moderate to Severe Ulcerative Colitis
Latest Information Update: 01 Sep 2025
At a glance
- Drugs Amelenodor (Primary)
- Indications Ulcerative colitis
- Focus Proof of concept; Therapeutic Use
- Acronyms NEXUS
- Sponsors AbbVie; Landos Biopharma
Most Recent Events
- 01 Jul 2025 Status changed from active, no longer recruiting to discontinued.
- 10 Jun 2025 Planned number of patients changed from 80 to 97.
- 19 Sep 2024 Status changed from recruiting to active, no longer recruiting.